Squarepoint
LRMR icon

Squarepoint’s Larimar Therapeutics LRMR Stock Holding History

Squarepoint’s Portfolio LRMR Stock Details LRMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-40,000
Closed -$304K – 4405
2024
Q1 		$304K Buy
+40,000
New +$312K ﹤0.01% 3373

Other funds holding LRMR

DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $665M AUM 95.48% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DCM
Defilade Capital Management Emeryville, California $747M AUM
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $524M AUM 164.42% 1-Year Est. Return

Squarepoint's LRMR Position: Q2 2026 in Review

Squarepoint opened a new position in Larimar Therapeutics (LRMR) in Q2 2026: 113,474 shares worth $346K. The stake represents ﹤0.01% of the portfolio and ranks #3701 among its holdings. This is a return to the name: Squarepoint previously reported a position in LRMR as recently as Q4 2025.

Squarepoint first reported a position in LRMR in Q4 2015 and has held it in 18 quarters since. The position peaked at $551K in Q3 2018. 163 funds tracked by Wall St. Rank hold LRMR as of Q2 2026.

  • Squarepoint held 113,474 shares of Larimar Therapeutics worth $346K as of Q2 2026.
  • Larimar Therapeutics was a new Squarepoint position in Q2 2026.
  • Larimar Therapeutics made up ﹤0.01% of Squarepoint's portfolio in Q2 2026, its #3701 holding.
  • Squarepoint first reported a position in Larimar Therapeutics in Q4 2015 and has held it in 18 quarters since.
  • Squarepoint's Larimar Therapeutics position peaked at $551K in Q3 2018.
  • 163 funds tracked by Wall St. Rank held Larimar Therapeutics as of Q2 2026.

Based on Squarepoint's 13F filing for Q2 2026, filed 14 Aug 2026.